m
Recent Posts
Connect with:
Friday / May 20.
HomeminewsARVO Shares MiSight 1 Day Data and Analysis

ARVO Shares MiSight 1 Day Data and Analysis

New data and analysis demonstrating the performance and efficacy of CooperVision’s MiSight 1 day contact lens is being shared at the 2022 Association for Research in Vision and Ophthalmology (ARVO) meeting in Denver, United States.

“The increasing severity and prevalence of myopia progression in children is one of the greatest healthcare issues today, with consequences that will last for generations,” said Paul Chamberlain, BSc (Hons), Director of Research Programs for CooperVision. “Our extensive scientific and commercial innovations have made it easier for eye care professionals to address this challenge and incorporate myopia management as the standard of care. The works we are presenting at ARVO build further confidence in MiSight 1 day contact lenses* as a preferred approach.”

… results indicate that treatment effects are retained regardless of when treatment ceased at any age between 14 to 18

Dual Focus Contact Lenses Induce Myopic Defocus in Children During Near Viewing (Meyer D, et al) presents evidence that myopia control using MiSight 1 day contact lenses is achieved through added myopic defocus, validating prior hypotheses.1 The study also quantified the myopic defocus dose delivered to children in two ways: by diopters and by the proportion of light focused in front of the retina. This work was conducted with the Indiana University School of Optometry.

Prior Myopia Control Effects Retained Upon Cessation of Dual-Focus Soft Contact Lens Wear (Hammond D, et al) offers further in-depth analysis of the seven-year MiSight 1 day clinical trial, which is the longest-running soft contact lens study among children. CooperVision previously reported that twelve months following treatment cessation, mean axial elongation data indicated no evidence of rebound effect, signifying the myopia control gains were retained among the entire cohort.2,3 †

This latest work provides a deeper dive into the year seven data. These results indicate that treatment effects are retained regardless of when treatment ceased at any age between 14 to 18. The investigators conclude that starting MiSight 1 day at a younger age and continuing throughout teenage years reduces time during which untreated eye growth can occur.4

View other ARVO 2022 research presentations at arvo.org/annual-meeting.

Disclaimer: The stability of the myopia reduction effect one-year post-treatment is being further evaluated in a post-approval study in the United States as a condition of FDA approval of MiSight 1 day.

Preliminary international study data shows that, on average, for children that discontinued treatment at age 14-19 following three or six years of MiSight 1 day wear, the eye growth reverted to age-expected average myopic progression rates.

* U.S. Indications for Use: MiSight 1 day (omafilcon A) soft (hydrophilic) contact lenses for daily wear are indicated for the correction of myopic ametropia and for slowing the progression of myopia in children with non-diseased eyes, who at the initiation of treatment are eight to12 years of age and have a refraction of -0.75 to -4.00 diopters (spherical equivalent) with ≤ 0.75 diopters of astigmatism. The lens is to be discarded after each removal.

 

References

  1. Meyer D, et al. Dual Focus Contact Lenses Induce Myopic Defocus in Children During Near Viewing. ARVO 2022 poster presentation.
  2. Chamberlain P, Arumugam B, et al. Myopia Progression on Cessation of Dual-Focus Contact Lens Wear: MiSight 1 day 7-Year Findings. Optom Vis Sci 2021;98:E-abstract 210049
  3. Hammond D, Arumugam B, et al. Myopia Control Treatment Gains are Retained after Termination of Dual-focus Contact Lens Wear with No Evidence of a Rebound Effect. Optom Vis Sci 2021;98:E-abstract 215130
  4. Hammond D, et al. Prior Myopia Control Effects Retained Upon Cessation of Dual-Focus Soft Contact Lens Wear. ARVO 2022 poster presentation.

DECLARATION

DISCLAIMER : THIS WEBSITE IS INTENDED FOR USE BY HEALTHCARE PROFESSIONALS ONLY.
By agreeing & continuing, you are declaring that you are a registered Healthcare professional with an appropriate registration. In order to view some areas of this website you will need to register and login.
If you are not a Healthcare professional do not continue.